InterMune, Inc. has entered into a new supply agreement with Boehringer Ingelheim Austria GmbH for Actimmune, eliminating InterMune’s $91.6 million in future purchase commitments that existed under the previous supply agreement. InterMune will pay BI Austria approximately $5.5 million. Under the terms of the new supply agreement, InterMune is not required to make any minimum annual purchase commitments and BI Austria is not required to commit to reserving any minimum annual capacity for th...